The quantitative/qualitative changes of hepatocellular carcinoma cells mixed in autologous blood salvaged during liver transplantation after cancer cell filtration using a leukocyte depletion filter and cancer cell heating using a rapid fluid warmer
Not Applicable
- Conditions
- Neoplasms
- Registration Number
- KCT0007207
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Hepatocelluar carcinoma patient undergoing liver transplantaion who are eligible for authotransfusion (18American society of anesthesia (ASA) class I - III
A person who consented to the clinical trial and signed the informed consent form
Exclusion Criteria
- If there is a contraindication for autologous blood transfusion
- If autologous blood transfusion is not performed
- If the patient has liver cancer other than hepatocellular carcinoma (e.g. Cholangiocarcinoma or metastatic liver tumor)
- Patients who did not consent to participate in the clinical trial
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quantification of circulating tumor cells
- Secondary Outcome Measures
Name Time Method Viability of circulating tumor cells